After a median follow-up of @ months , there was no significant difference between the ivabradine group and the placebo group in the incidence of the primary end point ( @ % and @ % , respectively ; hazard ratio , @ ; @ % confidence interval , @ to @ ; P = @ ) , nor were there significant differences in the incidences of death from cardiovascular causes and nonfatal myocardial infarction .